Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANL NASDAQ:BNTC NASDAQ:PRLD NASDAQ:UNCY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANLAdlai Nortye$11.60+1.7%$12.20$0.88▼$17.25$466.08M0.94460,076 shs109,309 shsBNTCBenitec Biopharma$13.30+4.7%$11.83$9.85▼$16.76$458.50M0.27139,255 shs22,362 shsPRLDPrelude Therapeutics$5.37+9.0%$4.35$0.75▼$5.69$433.27M1416,956 shs628,681 shsUNCYUnicycive Therapeutics$4.84-37.1%$7.55$3.71▼$8.74$133.02M1.74863,847 shs17.30 million shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANLAdlai Nortye+14.10%+9.71%-4.44%+64.88%+597.86%BNTCBenitec Biopharma+2.67%+3.25%+9.86%+19.25%+11.89%PRLDPrelude Therapeutics+12.56%+14.12%+25.77%+44.15%+527.79%UNCYUnicycive Therapeutics+7.99%-2.16%+4.34%+17.02%+13.24%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANLAdlai Nortye$11.60+1.7%$12.20$0.88▼$17.25$466.08M0.94460,076 shs109,309 shsBNTCBenitec Biopharma$13.30+4.7%$11.83$9.85▼$16.76$458.50M0.27139,255 shs22,362 shsPRLDPrelude Therapeutics$5.37+9.0%$4.35$0.75▼$5.69$433.27M1416,956 shs628,681 shsUNCYUnicycive Therapeutics$4.84-37.1%$7.55$3.71▼$8.74$133.02M1.74863,847 shs17.30 million shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANLAdlai Nortye+14.10%+9.71%-4.44%+64.88%+597.86%BNTCBenitec Biopharma+2.67%+3.25%+9.86%+19.25%+11.89%PRLDPrelude Therapeutics+12.56%+14.12%+25.77%+44.15%+527.79%UNCYUnicycive Therapeutics+7.99%-2.16%+4.34%+17.02%+13.24%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANLAdlai Nortye 2.67Moderate Buy$24.25109.03% UpsideBNTCBenitec Biopharma 2.56Moderate Buy$27.00103.01% UpsidePRLDPrelude Therapeutics 2.40Hold$7.6742.66% UpsideUNCYUnicycive Therapeutics 2.67Moderate Buy$23.00375.11% UpsideCurrent Analyst Ratings BreakdownLatest UNCY, PRLD, BNTC, and ANL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/30/2026UNCYUnicycive Therapeutics B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$22.006/30/2026UNCYUnicycive Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$22.00 ➝ $15.006/22/2026ANLAdlai Nortye Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight6/10/2026BNTCBenitec Biopharma GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral6/9/2026UNCYUnicycive Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/2/2026UNCYUnicycive Therapeutics BenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSpeculative Buy$15.00 ➝ $18.005/28/2026ANLAdlai Nortye OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$32.005/27/2026UNCYUnicycive Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$22.005/14/2026ANLAdlai Nortye JonesTradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$22.005/13/2026UNCYUnicycive Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$40.00 ➝ $37.005/12/2026BNTCBenitec Biopharma EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$25.00(Data available from 6/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANLAdlai Nortye$5M92.81N/AN/A($0.21) per share-55.24BNTCBenitec Biopharma$80K5,710.69N/AN/A$3.71 per share3.58PRLDPrelude Therapeutics$16.72M25.60N/AN/A$1.09 per share4.93UNCYUnicycive TherapeuticsN/AN/AN/AN/A$1.41 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANLAdlai Nortye-$35.53MN/AN/AN/AN/AN/AN/AN/A8/6/2026 (Estimated)BNTCBenitec Biopharma-$37.92M-$1.14N/AN/AN/AN/A-34.82%-34.11%N/APRLDPrelude Therapeutics-$99.50M-$1.00N/AN/AN/AN/A-118.24%-66.12%8/13/2026 (Estimated)UNCYUnicycive Therapeutics-$26.56M-$2.21N/A0.46N/AN/A-134.69%-84.51%8/13/2026 (Estimated)Latest UNCY, PRLD, BNTC, and ANL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q3 2026BNTCBenitec Biopharma-$0.27-$0.24+$0.03-$0.24$4.55 millionN/A5/12/2026Q1 2026PRLDPrelude Therapeutics-$0.27-$0.13+$0.14-$0.13$4.58 million$4.58 million5/12/2026Q1 2026UNCYUnicycive Therapeutics-$0.4589-$0.54-$0.0811-$0.54$11.11 millionN/A3/30/2026Q4 2025UNCYUnicycive Therapeutics-$0.46-$0.82-$0.36-$0.82$0.52 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthANLAdlai NortyeN/AN/AN/AN/AN/ABNTCBenitec BiopharmaN/AN/AN/AN/AN/APRLDPrelude TherapeuticsN/AN/AN/AN/AN/AUNCYUnicycive TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANLAdlai NortyeN/A0.650.65BNTCBenitec BiopharmaN/A56.8256.82PRLDPrelude TherapeuticsN/A2.032.03UNCYUnicycive TherapeuticsN/A2.402.40Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANLAdlai Nortye35.21%BNTCBenitec Biopharma52.19%PRLDPrelude Therapeutics79.72%UNCYUnicycive Therapeutics40.42%Insider OwnershipCompanyInsider OwnershipANLAdlai NortyeN/ABNTCBenitec Biopharma4.80%PRLDPrelude Therapeutics49.20%UNCYUnicycive Therapeutics6.03%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANLAdlai Nortye12740.00 millionN/ANot OptionableBNTCBenitec Biopharma2034.35 million32.71 millionNo DataPRLDPrelude Therapeutics12079.65 million40.46 millionOptionableUNCYUnicycive Therapeutics927.39 million25.74 millionNot OptionableUNCY, PRLD, BNTC, and ANL HeadlinesRecent News About These CompaniesJohnson Fistel Investigates Unicycive Therapeutics, Inc. (NASDAQ: UNCY) on Behalf of Investors1 hour ago | globenewswire.comUnicycive Therapeutics Receives FDA Complete Response Letter for Resubmitted OLC NDA, Citing Third-Party Manufacturing DeficienciesJune 30 at 7:31 AM | quiverquant.comQUnicycive Therapeutics Receives Complete Response Letter from FDA Regarding Resubmitted Oxylanthanum Carbonate (OLC) New Drug Application (NDA)June 30 at 7:05 AM | globenewswire.comUnicycive Therapeutics (NASDAQ:UNCY) Downgraded to Sell Rating by Wall Street ZenJune 27 at 1:31 AM | americanbankingnews.comUnicycive Therapeutics, Inc. Common Stock (UNCY) Insider ActivityJune 27 at 1:26 AM | nasdaq.comUNCY Share News TodayJune 24, 2026 | uk.investing.comUnicycive Therapeutics, Inc. (NASDAQ:UNCY) Receives Average Recommendation of "Moderate Buy" from BrokeragesJune 24, 2026 | americanbankingnews.comUnicycive seeks to distinguish OLC in crowded CKD hyperphosphatemia marketJune 22, 2026 | msn.comUnicycive Expands At-The-Market Equity Offering ProgramJune 5, 2026 | tipranks.comAnalysts Offer Insights on Healthcare Companies: Qiagen (QGEN) and Unicycive Therapeutics (UNCY)June 5, 2026 | theglobeandmail.comUnicycive Therapeutics: A Catalyst Play With Real Fundamental UpsideMay 21, 2026 | seekingalpha.comUnicycive Therapeutics Inc Ordinary Shares UNCYMay 16, 2026 | morningstar.comMUnicycive Therapeutics (UNCY) price target decreased by 23.53% to 32.20May 14, 2026 | msn.comUnicycive Therapeutics (UNCY) Pivots From Profit To Loss And Expands Equity Pool Is The Story Changing?May 14, 2026 | finance.yahoo.comUnicycive Therapeutics, Inc.: Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business UpdateMay 12, 2026 | finanznachrichten.deUnicycive Therapeutics Provides Update on FDA Review and Financial Results Ahead of OLC Launch PreparationsMay 12, 2026 | quiverquant.comQUnicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business UpdateMay 12, 2026 | globenewswire.comUnicycive Therapeutics, Inc. (UNCY) Presents at 25th Annual Needham Virtual Healthcare Conference TranscriptApril 16, 2026 | seekingalpha.comUnicycive Therapeutics Inc.April 11, 2026 | barrons.comKuehn Law Encourages Investors of Unicycive Therapeutics, Inc. to Contact Law FirmApril 9, 2026 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeUNCY, PRLD, BNTC, and ANL Company DescriptionsAdlai Nortye NASDAQ:ANL$11.60 +0.19 (+1.67%) As of 02:32 PM Eastern This is a fair market value price provided by Massive. Learn more.Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.Benitec Biopharma NASDAQ:BNTC$13.30 +0.60 (+4.72%) As of 02:32 PM Eastern This is a fair market value price provided by Massive. Learn more.Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.Prelude Therapeutics NASDAQ:PRLD$5.37 +0.44 (+9.01%) As of 02:33 PM Eastern This is a fair market value price provided by Massive. Learn more.Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.Unicycive Therapeutics NASDAQ:UNCY$4.84 -2.86 (-37.13%) As of 02:33 PM Eastern This is a fair market value price provided by Massive. Learn more.Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Wall Street Still Sees Massive Upside for AeroVironment Stock Manchester United’s Stock Rally Faces a Test Beyond Old Trafford Why AppLovin’s CEO Is Selling While Quantum Insiders Are Buying Volkswagen’s 16-Year Low Masks a Massive Margin Engine Palantir’s Rough 2026 Start Raises a Bigger Question About Its AI Moat Overclocking Qualcomm: Rewiring the AI Compute Market SpaceX Achieves Escape Velocity With Nasdaq Fast-Track 3 Top Financial Institutions Announce Over $70 Billion in Share Repurchases Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
